Predictive Oncology Statistics
Share Statistics
Predictive Oncology has 6.67M shares outstanding. The number of shares has increased by 64.09% in one year.
| Shares Outstanding | 6.67M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 6.52M |
| Failed to Deliver (FTD) Shares | 1.33K |
| FTD / Avg. Volume | 1.14% |
Short Selling Information
The latest short interest is 148.96K, so 2.23% of the outstanding shares have been sold short.
| Short Interest | 148.96K |
| Short % of Shares Out | 2.23% |
| Short % of Float | 2.28% |
| Short Ratio (days to cover) | 1.26 |
Valuation Ratios
The PE ratio is -0.94 and the forward PE ratio is -6.56.
| PE Ratio | -0.94 |
| Forward PE | -6.56 |
| PS Ratio | 7.42 |
| Forward PS | 0.5 |
| PB Ratio | 1.6 |
| P/FCF Ratio | -0.98 |
| PEG Ratio | n/a |
Enterprise Valuation
Predictive Oncology Inc. has an Enterprise Value (EV) of 7.34M.
| EV / Earnings | -0.52 |
| EV / Sales | 4.12 |
| EV / EBITDA | -0.56 |
| EV / EBIT | -0.53 |
| EV / FCF | -0.54 |
Financial Position
The company has a current ratio of 2.55, with a Debt / Equity ratio of 0.02.
| Current Ratio | 2.55 |
| Quick Ratio | 2.43 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 1.79 |
| Cash Flow / Debt | -87.69 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.69% and return on capital (ROIC) is -125.1%.
| Return on Equity (ROE) | -1.69% |
| Return on Assets (ROA) | -0.97% |
| Return on Capital (ROIC) | -125.1% |
| Revenue Per Employee | 52.36K |
| Profits Per Employee | -411.29K |
| Employee Count | 34 |
| Asset Turnover | 0.12 |
| Inventory Turnover | 1.28 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -62.06% in the last 52 weeks. The beta is 1.15, so Predictive Oncology 's price volatility has been higher than the market average.
| Beta | 1.15 |
| 52-Week Price Change | -62.06% |
| 50-Day Moving Average | 0.77 |
| 200-Day Moving Average | 1.13 |
| Relative Strength Index (RSI) | 71.78 |
| Average Volume (20 Days) | 116.69K |
Income Statement
In the last 12 months, Predictive Oncology had revenue of 1.78M and earned -13.98M in profits. Earnings per share was -3.48.
| Revenue | 1.78M |
| Gross Profit | 1.15M |
| Operating Income | -13.92M |
| Net Income | -13.98M |
| EBITDA | -13.18M |
| EBIT | -13.92M |
| Earnings Per Share (EPS) | -3.48 |
Balance Sheet
The company has 8.73M in cash and 2.86M in debt, giving a net cash position of 5.87M.
| Cash & Cash Equivalents | 8.73M |
| Total Debt | 2.86M |
| Net Cash | 5.87M |
| Retained Earnings | -167.76M |
| Total Assets | 7.50M |
| Working Capital | 750.64K |
Cash Flow
In the last 12 months, operating cash flow was -13.19M and capital expenditures -302.37K, giving a free cash flow of -13.49M.
| Operating Cash Flow | -13.19M |
| Capital Expenditures | -302.37K |
| Free Cash Flow | -13.49M |
| FCF Per Share | -3.36 |
Margins
Gross margin is 6.43K%, with operating and profit margins of -78.21K% and -78.56K%.
| Gross Margin | 6.43K% |
| Operating Margin | -78.21K% |
| Pretax Margin | -78.56K% |
| Profit Margin | -78.56K% |
| EBITDA Margin | -740.52% |
| EBIT Margin | -782.06% |
| FCF Margin | -757.92% |
Dividends & Yields
POAI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -294.92% |
| FCF Yield | -171.5% |
Analyst Forecast
The average price target for POAI is $3, which is 154.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $3 |
| Price Target Difference | 154.2% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Apr 24, 2023. It was a backward split with a ratio of 1:20.
| Last Split Date | Apr 24, 2023 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -38.25 |
| Piotroski F-Score | 3 |